United Therapeutics Acquires Thymmune Therapeutics for ~$300M

Shots: United Therapeutics has acquired Thymmune Therapeutics, incl. its lead asset THY-100, developed for the treatment of congenital athymia Under the deal, United Therapeutics has acquired Thymmune for $140M upfront, with up to $160M in additional earn-out payments tied to clinical & regulatory milestones through 2031 THY-100 is a preclinical regenerative therapy for congenital athymia that showed formation of an in vivo neo-thymus to restore T-cell development, with potential applications in transplant tolerance, immune-mediated diseases, & age-related immune decline Ref: Businesswire  |  Image:  Thymmune  |  Press Release Related News: Ipsen to Acquire Kartos Therapeutics for ~$1.75B PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post United Therapeutics Acquires Thymmune Therapeutics for ~$300M appeared first on PharmaShots.